Genflow Biosciences (LSE:GENF) more than halved administrative expenses in the first half of 2026 and ended June with £632,553 in cash. Its directors still flag a material uncertainty over Going Concern as the company prepares to present full results from its canine healthspan trial on 2 October.
What was announced
Genflow Biosciences Plc (LSE:GENF), which develops SIRT6 gene therapies for age-related diseases, published unaudited half-year results for the six months to 30 June 2026. All of its human health programmes also moved onto a messenger RNA-lipid nanoparticle (mRNA-LNP) delivery platform.
The company's main near-term event is in animal health. It has completed GF-1004, a comparative, randomised healthspan and sarcopenia trial in aged Beagle dogs known as SLAB, which used a naked DNA construct. Full results are due to be presented at the Animal Longevity Summit in Toronto on 2 October 2026.
The numbers
The net loss for the half was £420,233, and the operating loss was £419,728, compared with an operating loss of £737,618 in the first half of 2025. Costs fell sharply:
- Administrative expenses: £454,311 (H1 2025: £982,725)
- R&D costs: £119,445 (H1 2025: £665,862)
- Directors' fees: £126,547 (H1 2025: £55,272)
- Loss per share: 0.080p (H1 2025: 0.192p)
Cash was £632,553 at 30 June 2026, compared with £111,792 at 31 December 2025 and £279,445 a year earlier. Net Assets were £189,853, compared with net liabilities of £550,785 at the 2025 year end. The company is debt-free.
That improvement came from three share issues that raised £1,159,375 gross, or £1,148,875 after £10,500 of issue costs. On 11 March 2026 the company issued 42.1 million shares at 1.9p to raise £800,000. On 13 May it issued 2.6 million shares at 1.9p for £50,000 and 28.1 million shares at 1.1p for £309,375. There were 566.4 million shares in issue at 30 June, up from 493.5 million at the end of 2025. Based on the disclosed figures, that is an increase of about 15% in the share count over six months.
The directors state that "a material uncertainty related to going concern exists". They also say the company "has adequate Working Capital to execute its operations for the present time" and is "confident in its ability to access additional financing over the next 12 months".
Pipeline and background
According to the company, the SLAB trial confirmed safety and tolerability and generated functional and healthspan data. A scientific manuscript is being prepared for peer-reviewed publication, and Genflow says it is in several confidential discussions with animal health companies. No counterparties or commercial terms have been disclosed. Chairman Gad Berdugo said completing the trial "validates our SIRT6 centenarian platform in a real-world aging population".
In human health, GF-1002 has been repositioned to target advanced metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, in a population that responds to antifibrotic treatment. The programme moved to mRNA-LNP delivery during the half. The company is also seeking an extension of a non-dilutive grant from the Wallonia Region.
A new glaucoma programme, GF-1006, began during the period in Partnership with Iris Pharma and Acuitas and will use Acuitas' LNP technology for delivery to the eye. The company says preclinical findings suggest that SIRT6 overexpression may protect retinal ganglion cells. Its Mitosir and Exofastrack programmes are being developed in mRNA-LNP formulations with the support of grant funding.
What to watch next
The Toronto presentation on 2 October will be the first Full Disclosure of the SLAB data. Genflow's stated priorities for the rest of 2026 and into 2027 are:
- advancing its talks with animal health companies
- speeding up the glaucoma programme
- progressing its MASH work
- securing non-dilutive funding, including the extension of the Wallonia grant
Given the going-concern statement and a cash balance of about £0.63m, any news on further financing will also be relevant. The company has not disclosed its cash runway.






Please wait processing your request...